- Oops!Something went wrong.Please try again later.
Infinity Pharmaceuticals Inc (NASDAQ: INFI) has announced a data presentation from MARIO-275 Phase 2 study evaluating eganelisib combined with Bristol-Myers Squibb's Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer at the 2021 ASCO Genitourinary Cancers Symposium.
In the overall population, the combination of eganelisib with nivolumab demonstrated an increase over nivolumab monotherapy in overall response rate (30% vs. 25%); disease control rate (55% vs. 31%); best responses of complete response (12% vs. 6%); stable disease (24% vs. 6%).
Data also showed that the addition of eganelisib on top of 2L standard of care nivolumab was well-tolerated and led to clear benefits for PD-L1 low patients, with an over 85% increase in ORR vs. the control arm.
PD-L1 negative patients demonstrated an extended progression-free survival, reflecting a 46% reduction in the probability of progression of 9.1 weeks on the combination arm versus 7.9 weeks on the control arm.
Increased immune activation and decreased immune suppression were observed in combination therapy compared to monotherapy across PD-L1 negative and positive patients.
Registration-enabling study in PD-L1 low metastatic urothelial cancer is planned next.
Price Action: INFI stock increased 20% at $4.74 in premarket trading on the last check Thursday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.